Physician profile
Abhijeet Kumar
NPI 1134409923
$66,268.04
in general payments reported to CMS, 2019-2025
30 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,991 · 2020: $1,876 · 2023: $37.40 · 2024: $15K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $14K · Travel and Lodging: $7,043 · Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,780.00 |
| Consulting Fee | $13,840.00 |
| Travel and Lodging | $7,043.02 |
| Food and Beverage | $1,738.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $28,119.38 | 2025 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $19,967.09 | 2020-2025 | Calquence |
| Adc Therapeutics America, INC. | $11,034.25 | 2024 | |
| Kyowa Kirin, INC. | $3,850.12 | 2019 | |
| Abbvie INC. | $2,958.94 | 2025 | |
| Seagen INC. | $99.00 | 2019 | |
| Pfizer INC. | $50.51 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.43 | 2019-2024 | Alunbrig |
| Genentech USA, INC. | $37.40 | 2023 | Polivy, Lunsumio |
| Genzyme Corporation | $28.71 | 2024 | |
| Geron Corporation | $22.68 | 2025 | Rytelo |
| Janssen Biotech, INC. | $20.51 | 2024 | Tecvayli, Talvey |
| Tempus Ai, INC | $20.00 | 2025 | Xt Cdx |
| Secura Bio, INC. | $15.02 | 2019 |
16 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijeet Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.